ImmunityBio (NASDAQ: IBRX) Just Broke Out on a HUGE Catalyst Setup – Could Soar 36%-59% Higher
IBRX’s latest move reflects a powerful confluence of developments — commercial, regulatory, and strategic — that have come together in rapid succession to fundamentally reframe the company’s near-term growth trajectory.
Read More

